A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

Phase 1 Completed 52 enrolled Eli Lilly and Company

Non-randomizedSequentialOpen-labelTreatment

Summary

A dose escalation study to establish the safety profile and characterize the pharmacokinetic profile of IMC-CS4 in the treatment of subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available.

Timeline

Start: 2011-06-15
Primary completion: 2018-05-31
Completion: 2018-05-31

Publications

Dowlati A, Harvey RD, Carvajal RD, Hamid O, Klempner SJ, Kauh JSW, Peterson DA, Yu D, Chapman SC, Szpurka AM, Carlsen M, Quinlan T, Wesolowski R. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. Invest New Drugs. 2021 Aug;39(4):1057-1071. doi: 10.1007/s10637-021-01084-8. Epub 2021 Feb 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IMC-CS4	Monoclonal antibody	0.3 mg/kg	Intravenous
Subject	IMC-CS4	Monoclonal antibody	0.6 mg/kg	Intravenous
Subject	IMC-CS4	Monoclonal antibody	1.25 mg/kg	Intravenous
Subject	IMC-CS4	Monoclonal antibody	2.5 mg/kg	Intravenous
Subject	IMC-CS4	Monoclonal antibody	100 mg	Intravenous
Subject	IMC-CS4	Monoclonal antibody	150 mg	Intravenous

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications